Morgan Stanley raised its price target for Neurocrine Biosciences from $185 to $191 while keeping a 'Neutral' rating.

Nov 13, 2026, 9:38 AM ETOpinionRead the original at moomoo.com

Neutral

Morgan Stanley raised its target from $185 to $191 but kept its Neutral rating. The story reports no change in Neurocrine's business, so it does not change the company's outlook.

NBIX · Neurocrine Biosciences, Inc.

AI read · Neutral

The AI's read

The higher target points to a more positive analyst view. But the analyst kept a Neutral rating, and the story reports no change in Neurocrine's business. Together, these facts do not show a clear change in the company's outlook.

Get alerts for NBIX

Follow Neurocrine Biosciences, Inc. (NBIX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NBIX

Free on the App Store and Google Play, or on the web.